- Report
- March 2024
- 196 Pages
Global
From €3257EUR$3,374USD£2,794GBP
€3619EUR$3,749USD£3,104GBP
- Report
- November 2023
- 175 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- April 2024
- 94 Pages
Global
From €5405EUR$5,600USD£4,637GBP
- Report
- May 2023
- 144 Pages
Global
From €2412EUR$2,499USD£2,069GBP
- Report
- November 2023
- 142 Pages
Global
From €2412EUR$2,499USD£2,069GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Report
- January 2024
- 175 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- March 2024
- 183 Pages
Global
From €2413EUR$2,500USD£2,070GBP
- Report
- March 2022
- 300 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- January 2022
- 117 Pages
Global
From €4585EUR$4,750USD£3,933GBP
- Report
- January 2022
- 200 Pages
Global
From €7239EUR$7,500USD£6,210GBP
- Report
- September 2023
- 90 Pages
Egypt
From €3378EUR$3,500USD£2,898GBP
- Report
- August 2023
- 73 Pages
Israel
From €3378EUR$3,500USD£2,898GBP
- Report
- August 2022
United States
From €1872EUR$1,940USD£1,606GBP
- Report
- August 2022
Global
From €1052EUR$1,090USD£902GBP
- Report
- February 2021
Global
From €2857EUR$2,960USD£2,451GBP
- Clinical Trials
- January 2020
- 807 Pages
Global
From €2413EUR$2,500USD£2,070GBP
- Report
- May 2022
- 146 Pages
Global
From €2413EUR$2,500USD£2,070GBP
- Report
- December 2019
- 184 Pages
Global
From €5183EUR$5,370USD£4,446GBP
- Report
- September 2023
- 160 Pages
Global
From €2895EUR$2,999USD£2,483GBP
The Hyperlipidemia Drug market is a subset of the Cardiovascular Drugs market, which focuses on the treatment of high levels of lipids in the blood. Hyperlipidemia is a condition that can lead to an increased risk of heart disease, stroke, and other cardiovascular diseases. Common treatments for hyperlipidemia include statins, fibrates, and cholesterol absorption inhibitors. Statins are the most commonly prescribed drugs for hyperlipidemia, as they are effective in reducing cholesterol levels. Fibrates are used to reduce triglyceride levels, while cholesterol absorption inhibitors reduce the absorption of cholesterol from the diet.
Some companies in the Hyperlipidemia Drug market include Pfizer, Merck, AstraZeneca, Sanofi, and Bristol-Myers Squibb. Show Less Read more